#Shanghai #USA #Sickle Cell #CorrectSequence #Base Editing

Transformative Base Editing Therapy for Sickle Cell Disease

In an exciting development in the field of hematology, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company, has reported significant advancements with its pioneering transformer Base Editing (tBE) technology aimed at treating severe hematologic conditions. Their latest findings highlight the positive response of their therapy, CS-206, on patients suffering from sickle cell disease (SCD), demonstrating effectiveness free from vaso-occlusive crises (VOCs) for over 15 months.

In a remarkable case, a 21-year-old Nigerian female patient treated with CS-206 experienced a transformation in her health status following treatment initiated in February 2025. This individual had a history of recurrent severe VOCs prior to the therapy. However, post-treatment, she showed rapid and efficient haematopoietic reconstitution, achieving notable milestones: neutrophil engraftment was observed by Day 13, and her platelet count surpassed 50 x 10^9/L by Day 21. Impressively, fetal hemoglobin (HbF) levels surged within the first month after treatment while the levels of sickle hemoglobin (HbS) experienced a sustained decline.

The data collected during the 15-month follow-up reveals that the patient not only reached but maintained the primary efficacy endpoint of being free from anemia and VOCs since 60 days after her last erythrocyte transfusion. Such findings illustrate the compelling safety and efficacy profile of CS-206, which leverages Correctseq's advanced tBE technology that precisely targets and edits genes in the patient's hematopoietic stem cells. This unique approach mimics naturally occurring positive mutations found in healthy individuals, reactivating γ-globin expression and significantly increasing the fetal hemoglobin levels.

Importantly, CS-206 operates without causing double-strand breaks, a common risk found in traditional CRISPR-based gene-editing therapies, thereby reducing the chance of unwanted genomic deletions and chromosomal abnormalities. Data presented from this therapy suggests that not only does it effectively avert the sickling of red blood cells, but it also significantly decreases complications stemming from hemolysis and crisis events.

Sickle Cell Disease, caused by mutations in the β-globin gene, leads to chronic anemia and frequent painful crises, often resulting in severe organ damage. Approximately 3.5% of the global population carries the sickle cell mutation, with around 300,000 newborns diagnosed with this condition each year, particularly in regions such as Africa, the Mediterranean, the Middle East, and South Asia. When considering both SCD and β-thalassemia, these disorders are among the most common monogenic diseases worldwide, affecting approximately 7% of the population.

In another exciting avenue, Correctseq is advancing a similar therapy, CS-101, aimed at treating β-thalassemia. This particular therapy has already demonstrated success in over ten patients from multiple countries, maintaining transfusion independence for more than 15 months. This accomplishment paves the way for more potential treatments for patients afflicted with these blood disorders.

Currently, recruitment for an investigator-initiated trial (IIT) of CS-206 is ongoing, reflecting Correctseq's commitment to accelerating the clinical development of both CS-101 and CS-206, aiming to deliver safer, more effective, and affordable treatment options to patients suffering from hemoglobinopathies worldwide. The future of sickle cell and β-thalassemia therapies seems promising, thanks to novel biotechnological advancements from companies like CorrectSequence Therapeutics.

For more information about CorrectSequence Therapeutics and its innovative therapies, visit CorrectSequence Therapeutics.